India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Auto Tracker: VAHAN Dashboard Points to a Softer Cycle in India

Why India's Pharma Giants Are Betting on Chronic Business?

Anupam Rasayan’s Pharma Pivot: From Molecules to Medicines

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

India Pharmaceuticals, biotechnology and life sciences / Thematic (Sector/Industry)

<ul>
<li>Wockhardt’s Zaynich received CDSCO approval on 28 May 2026 and appeared on the US FDA Novel Drug Approvals list on 29 May, potentially marking a first US-approved Indian pharma NCE</li>
<li>Zaynich targets MDR/XDR gram-negative superbugs with first-in-class beta-lactam enhancer mechanism. The company estimates a <strong>$7 billion addressable market in US and Europe</strong>, plus a Rs 17,000 crore opportunity in India.</li>
<li>Regulatory approvals shift the risk profile from scientific to commercial. The real test begins now: pricing, hospital adoption, and whether the revenue ramp can validate over decade of R&amp;D investment.</li>
</ul>


Wockhardt’s Zaynich received CDSCO approval on 28 May 2026 and appeared on the US FDA Novel Drug Approvals list on 29 May, potentially marking a first US-approved Indian pharma NCE
Zaynich targets MDR/XDR gram-negative superbugs with first-in-class beta-lactam enhancer mechanism. The company estimates a $7 billion addressable market in US and Europe, plus a Rs 17,000 crore opportunity in India.
Regulatory approvals shift the risk profile from scientific to commercial. The real test begins now: pricing, hospital adoption, and whether the revenue ramp can validate over decade of R&amp;D investment.


Zaynich Approvals: How Wockhardt Could Unlock a $7 Billion Opportunity